||This article has been edited in return for disclosed payments. View disclosure.|
|Industry||Dietary supplements, food ingredients|
|Headquarters||Irvine, California, United States|
ChromaDex has licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound trademarked as pTeroPure via the company's BluScience product line. In 2011, Cornell University announced it granted ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside which it markets and sells as an ingredient under the brand name Niagen.
ChromaDex sells ingredients to third parties that market them under their own labels. Elysium Health bought the ingredients in its "Basis" product from ChromaDex. ChromaDex and Elysium had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the head of manufacturing from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.
- Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Retrieved 2012-05-25.
- "Got nicotinamide riboside?". Life Extension. 2007-05-04. Retrieved 2012-05-29.
- "OTC Markets Stock Profile CDXC". OTC Markets. Retrieved 2016-03-21.
- "ChromaDex Corp. Names Consumer Products Veteran Jeffrey Himmel CEO". 2012-01-23. Retrieved 2012-05-29.
- Zhang, Sarah (July 6, 2016). "The Weird Business Behind a Trendy "Anti-Aging" Pill". Wired.
- Buhr, Sarah (January 16, 2017). "A new lawsuit alleges anti-aging startup Elysium Health hasn't paid its sole supplier". TechCrunch.